Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment.
The PD-L1 assay and the AccuCyte-CyteFinder system processes a single tube of blood to cells for CTC enumeration and PD-L1 biomarker expression analysis, and to plasma for optional cfDNA analysis.
COVID-19 Compass is based on CDC guidelines, best clinical practices, illness severity, and risk factors such as age, gender, location, potential exposure and pre-existing health conditions.
EsoGuard is designed to facilitate the diagnosis of Barrett’s Esophagus (BE) and related precursors to highly lethal esophageal adenocarcinoma (EAC).
Using the kit, researchers can capture the complete transcriptome, including short (<200 bp) and long (>200 bp) RNAs, in a single library prep.
The kit is designed for purification of circulating cfNDA and uses silica coated paramagnetic particles to purify cfDNA from less than 1 mL to greater than 10 mL of serum or plasma.
Each of the new panels comes with ERASE-Seq, Fluxion's variant caller which uses statistical analysis to compare sequencing results across several molecular amplification pools.
Biocept's Target Selector test enables physicians to identify the potential presence of NTRK fusions used to inform on treatment options.
The new clinical report, Cardiac Care, features more than 110 genes from clinical databases spanning more than 30 different cardiovascular conditions, ranging from cardiomyopathies to rare forms of long QT syndromes.
NanoString Technologies has announced the launch of nCounter Human Organ Transplant, a gene expression panel for researchers to evaluate the human immune response following organ transplantation.